Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumor: early-phase trial registry
133 of 190 indexed Advanced Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #56 of 28,707 conditions by registered trial count.
190 US clinical trials · 133 currently recruiting · #56 of 28,707 conditions by registered trial count
Advanced Solid Tumor: 190 US clinical trials tracked, 133 recruiting.
Advanced Solid Tumor is the subject of 190 registered US clinical trials on ClinicalTrials.gov, 133 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 186 in Phase 1-2 (earlier-stage). The most active sponsor is Daiichi Sankyo, running 7 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumor
OPEN 133 | RECR 70% | LATE 0 | EARLY 186 | RANK #56 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IV Breast Cancer AJCC v8 (70% recruiting · 60 trials)
Advanced Solid Tumor lists 133 open slots (70% of 190 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumor is recruiting above its size-band peers.
133 of 190 indexed trials (70%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Tumor trials is spread across many organizations.
Daiichi Sankyo accounts for 7 of 190 trials (3.7%). 135 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumor enrolment sits around 141 participants.
Median target enrolment is 141 among the 190 trials that report a genuine target (sentinel values excluded). 73 of those (38.4%) plan for fewer than 100 participants.
-
Advanced Solid Tumor research is mostly interventional.
188 interventional and 2 observational studies make up this index (98.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
190 total, page 3 of 4
AMT-116 in Patients With Advanced Solid Tumors
Multitude Therapeutics
NCT05725291
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
NCT05892718
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co.
NCT05417321
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
EMD Serono Research & Development Institute
NCT07166601
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
NCT06952010
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co.
NCT05038150
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
ARC101 in Advanced Solid Tumors
Third Arc Bio
NCT06672185
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
NCT06302621
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
TORL Biotherapeutics
NCT06005740
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
1200 Pharma
NCT05103046
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Peel Therapeutics
NCT05329103
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
Robert Bok, MD, PhD
NCT05599048
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
NCT07181681
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Impact Therapeutics
NCT05269316
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Barbara Ann Karmanos Cancer Institute
NCT07098299
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
NCT06130254
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono Research & Development Institute
NCT06641908
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Senhwa Biosciences
NCT04890613
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Schrödinger
NCT06463340
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Replimune
NCT06887348
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
FBD Biologics Limited
NCT06487624
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
TOLREMO therapeutics
NCT06403436
A Study of LM-24C5 For Advanced Solid Tumors
LaNova Medicines Limited
NCT06187402
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
NCT05901285
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Fox Chase Cancer Center
NCT04827810
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
SOTIO Biotech
NCT06163391
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
NCT06750185
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Ranok Therapeutics (Hangzhou) Co.
NCT05487170
First in Human, Dose Escalation Study of AN4005
Adlai Nortye Biopharma Co.
NCT04999384
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4
NCT06352359
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Aadi Bioscience
NCT05661461
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
University of Illinois at Chicago
NCT07269080
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT06607185
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4
NCT04140526
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Nuvation Bio
NCT06334432
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Cullinan Therapeutics
NCT05117476
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
NCT04561362
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT05081609
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
NCT05878691
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Janssen Research & Development
NCT04083976
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences
NCT05544552
QTX3046 in Patients With KRAS G12D Mutations
Quanta Therapeutics
NCT06428500
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines
NCT05462717
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma
NCT05898399
Meaning-Centered Pain Coping Skills Training for Cancer Pain
Duke University
NCT05385965
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT05585320
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
NCT05163041
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05156866
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
D2M Biotherapeutics
NCT06328673
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 180 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumor page
190 registered trials, 133 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 133 Advanced Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Daiichi Sankyo sponsors the most Advanced Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Daiichi Sankyo's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumor condition card totals 190 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.